AIG
AVTX icon

American International Group’s Avalo Therapeutics AVTX Stock Holding History

American International Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11
Closed -$22K – 3102
2022
Q1 		$22K Hold
11
– – ﹤0.01% 3015
2021
Q4 		$56K Buy
11
+1
+10% +$6K ﹤0.01% 2929
2021
Q3 		$63K Hold
10
– – ﹤0.01% 2952
2021
Q2 		$97 Buy
10
+1
+11% +$8.38K ﹤0.01% 2882
2021
Q1 		$76 Buy
9
+2
+29% +$18.9K ﹤0.01% 2831
2020
Q4 		$56 Sell
7
-1
-13% -$6.95K ﹤0.01% 2924
2020
Q3 		$49K Buy
8
+2
+33% +$15K ﹤0.01% 2886
2020
Q2 		$46K Buy
6
+1
+20% +$7.26K ﹤0.01% 2908
2020
Q1 		$33K Hold
5
– – ﹤0.01% 2821
2019
Q4 		$75K Hold
5
– – ﹤0.01% 2757
2019
Q3 		$45K Hold
5
– – ﹤0.01% 2911
2019
Q2 		$74K Buy
+5
New +$75.8K ﹤0.01% 2825

Other funds holding AVTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American International Group's AVTX Position: Q2 2022 in Review

American International Group sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 11 shares — an estimated $22K sold.

American International Group first reported a position in AVTX in Q2 2019 and held it in 12 quarters. The position peaked at $75K in Q4 2019. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

  • American International Group reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
  • American International Group sold 11 Avalo Therapeutics shares in Q2 2022, an estimated $22K.
  • American International Group first reported a position in Avalo Therapeutics in Q2 2019 and held it in 12 quarters.
  • American International Group's Avalo Therapeutics position peaked at $75K in Q4 2019.
  • 43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on American International Group's 13F filing for Q2 2022, filed 12 Aug 2022.